AU2001268250A1 - CD154 variants - Google Patents
CD154 variantsInfo
- Publication number
- AU2001268250A1 AU2001268250A1 AU2001268250A AU6825001A AU2001268250A1 AU 2001268250 A1 AU2001268250 A1 AU 2001268250A1 AU 2001268250 A AU2001268250 A AU 2001268250A AU 6825001 A AU6825001 A AU 6825001A AU 2001268250 A1 AU2001268250 A1 AU 2001268250A1
- Authority
- AU
- Australia
- Prior art keywords
- cell
- wildtype
- mutant
- amino acid
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21065700P | 2000-06-09 | 2000-06-09 | |
US60210657 | 2000-06-09 | ||
PCT/US2001/018517 WO2001096397A2 (fr) | 2000-06-09 | 2001-06-08 | Variants cd154 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001268250A1 true AU2001268250A1 (en) | 2001-12-24 |
Family
ID=22783741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001268250A Abandoned AU2001268250A1 (en) | 2000-06-09 | 2001-06-08 | CD154 variants |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1294874B1 (fr) |
JP (1) | JP2004503237A (fr) |
AT (1) | ATE325874T1 (fr) |
AU (1) | AU2001268250A1 (fr) |
CA (1) | CA2411472A1 (fr) |
CY (1) | CY1105153T1 (fr) |
DE (1) | DE60119517T2 (fr) |
DK (1) | DK1294874T3 (fr) |
ES (1) | ES2264697T3 (fr) |
NZ (1) | NZ523351A (fr) |
PT (1) | PT1294874E (fr) |
WO (1) | WO2001096397A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2467919A1 (fr) * | 2001-08-10 | 2003-02-20 | Roskamp Research, Llc | Procedes et composes permettant la fragmentation de la signalisation de cd40r/cd40l dans le traitement de la maladie d'alzheimer |
WO2005100558A1 (fr) * | 2004-04-16 | 2005-10-27 | Hokkaido | Mutant de ligand cd40 et utilisation de celui-ci |
CA2725162A1 (fr) * | 2008-05-22 | 2009-11-26 | Proyecto De Biomedicina Cima, S.L. | Molecule adaptateur pour l'administration de vecteurs adenoviraux |
US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3054632A1 (fr) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
WO2019246317A1 (fr) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP3870261B1 (fr) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Dispositif ingestible pour la livraison d'un agent thérapeutique au système gastro-intestinal |
-
2001
- 2001-06-08 AT AT01946167T patent/ATE325874T1/de not_active IP Right Cessation
- 2001-06-08 WO PCT/US2001/018517 patent/WO2001096397A2/fr active IP Right Grant
- 2001-06-08 EP EP01946167A patent/EP1294874B1/fr not_active Expired - Lifetime
- 2001-06-08 JP JP2002510534A patent/JP2004503237A/ja not_active Withdrawn
- 2001-06-08 DK DK01946167T patent/DK1294874T3/da active
- 2001-06-08 AU AU2001268250A patent/AU2001268250A1/en not_active Abandoned
- 2001-06-08 CA CA002411472A patent/CA2411472A1/fr not_active Abandoned
- 2001-06-08 NZ NZ523351A patent/NZ523351A/en unknown
- 2001-06-08 PT PT01946167T patent/PT1294874E/pt unknown
- 2001-06-08 DE DE60119517T patent/DE60119517T2/de not_active Expired - Fee Related
- 2001-06-08 ES ES01946167T patent/ES2264697T3/es not_active Expired - Lifetime
-
2006
- 2006-07-26 CY CY20061101033T patent/CY1105153T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE60119517T2 (de) | 2007-03-08 |
EP1294874B1 (fr) | 2006-05-10 |
ATE325874T1 (de) | 2006-06-15 |
CA2411472A1 (fr) | 2001-12-20 |
NZ523351A (en) | 2004-10-29 |
CY1105153T1 (el) | 2010-03-03 |
PT1294874E (pt) | 2006-09-29 |
DK1294874T3 (da) | 2006-08-28 |
EP1294874A2 (fr) | 2003-03-26 |
WO2001096397A3 (fr) | 2002-05-02 |
DE60119517D1 (de) | 2006-06-14 |
WO2001096397A2 (fr) | 2001-12-20 |
JP2004503237A (ja) | 2004-02-05 |
ES2264697T3 (es) | 2007-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10844117B2 (en) | Human alpha-folate receptor chimeric antigen receptor | |
JP5379107B2 (ja) | 免疫調節因子であるbaffレセプター(bcma) | |
JP2024056890A (ja) | 前立腺特異的膜抗原carおよびその使用方法 | |
US20060057102A1 (en) | Mutant interleukin-15-containing compositions and suppression of an immune response | |
EA031080B1 (ru) | МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα | |
JP2007191489A (ja) | 免疫調節因子としてのb7−h3の使用 | |
CZ2000490A3 (cs) | Interleukin-18-vazebné proteiny, příprava a použití | |
US20070065875A1 (en) | NTB-A, a surface molecule involved in natural killer cells activity | |
JP2020520985A (ja) | がん療法における免疫関連有害事象の治療のための可溶性cd24の使用方法 | |
US5830469A (en) | Fas antagonists and uses thereof | |
EP1294874B1 (fr) | Variants cd154 et leurs utilisations | |
JP2840131B2 (ja) | 液性免疫の持続性抑制方法 | |
AU2002325333A1 (en) | NTB-A, a surface molecule involved in natural killer cells activity | |
US20030212025A1 (en) | Cd154 variants | |
US20030148454A1 (en) | Virus-free vesicles for delivery of functional membrane bound proteins | |
AU2007201053A1 (en) | CD154 Variants | |
ES2301164T3 (es) | Slam, antigeno coestimulador de la superficie de celulas t. | |
WO2022196719A1 (fr) | Gène codant pour un récepteur chimérique pour auto-anticorps anti-récepteur de l'acétylcholine | |
WO2024140836A1 (fr) | Combinaison d'une protéine de fusion ciblant un ligand nkg2d et d'une cellule réceptrice d'antigène chimérique, et son utilisation | |
WO1999003999A1 (fr) | Procedes et compositions servant a inhiber la reaction proinflammatoire | |
CA2384115A1 (fr) | Techniques et compositions destinees au traitement de maladie inflammatoire par utilisation d'agents de modulation cadherine-11 | |
Sun et al. | Identification of CD226 ligand on colo205 cell surface | |
NZ567242A (en) | Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer | |
WO1999025737A1 (fr) | Compositions et procedes de traitement de maladies autoimmunes a l'aide d'un anticorps monoclonal se liant a la chaine interleukine-12 beta2 | |
WO1994022458A1 (fr) | Procedes pour augmenter les fonctions effectrices des cellules t cytotoxiques, utilisables en immunotherapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |